Cabaletta Bio (CABA) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($228.6 million vs $201.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | SCTX |
|---|---|---|
| Share price | $0.9361 | $12.07 |
| Market cap | $201.94M | $228.58M |
| 1-day change | -7.32% | -8.70% |
| YTD return | -57.26% | — |
| 1-year return | -55.00% | — |
| 5-year return | -91.93% | — |
| EPS (TTM) | $-1.33 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-167.86M | — |
| 52-week high | $4.23 | $39.60 |
| 52-week low | $0.93 | $12.00 |
| Distance from 52-week high | -77.87% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1155.21% | +372.25% |
| Average volume | 5.15M | 403.27K |
| Shares outstanding | 215.72M | 18.94M |
| Employees | 154 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
CABA vs SCTX FAQ
Which is bigger, Cabaletta Bio or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $201.94M for Cabaletta Bio (CABA).
Are Cabaletta Bio and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.